Skip to main content
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloproliferative neoplasms.

Christopher Carpenter, Ph.D.

  • E. Bronson Ingram Chair
  • University Distinguished Professor of Economics
  • University Distinguished Professor of Health Policy
  • Director of the Center for Research on Inequality and Health

Christopher Carpenter, Ph.D.

  • E. Bronson Ingram Chair
  • University Distinguished Professor of Economics
  • University Distinguished Professor of Health Policy
  • Director of the Center for Research on Inequality and Health

christopher.s.carpenter@vanderbilt.edu

Research Program

Have any questions? Contact Us 1-877-936-8422 for more information

Amanda Linkous, Ph.D.

  • Research Associate Professor of Pharmacology
  • Center Manager, NCI Center for Systems Biology of Small Cell Lung Cancer at Vanderbilt

Amanda Linkous, Ph.D.

  • Research Associate Professor of Pharmacology
  • Center Manager, NCI Center for Systems Biology of Small Cell Lung Cancer at Vanderbilt

amanda.linkous@Vanderbilt.Edu

Research Program

Research Description

Have any questions? Contact Us 1-877-936-8422 for more information

Study finds a role for AI in drug repurposing pipeline

Submitted by robbikm2 on

A research team led by Wei-Qi Wei, MD, PhD, reported their findings on February 26th in Nature Digital Medicine. Their study searched for new treatments for Alzheimer’s disease (AD) by asking ChatGPT whether any existing drugs used for other problems might help patients with AD. ChatGPT is a cloud-based artificial intelligence program, a so-called large language model that’s been optimized for chat.

This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase 1b of this clinical study is learn about the effectiveness of the recommended dose of KITE-197 in participants with r/r LBCL. The primary objectives of this study are: Phase 1a: To evaluate the safety of KITE-197 in participants with r/r LBCL and determine the target dose level for Phase 1b. Phase 1b: To evaluate the efficacy of KITE-197 in participants with r/r LBCL as measured by the complete remission (CR) rate.
Subscribe to